rawfin.tv
OptimizeRx Reaffirms 2026 Revenue Outlook Amid CFO Transition
MarketsstocksAI Generated

OptimizeRx Reaffirms 2026 Revenue Outlook Amid CFO Transition

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

OptimizeRx Corp. reiterated its 2026 revenue outlook of $95 million to $100 million. The announcement comes as the company navigates a transition in its Chief Financial Officer role.

Healthcare TechRevenue GuidanceExecutive Change

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks